Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

350 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, Polman C, McFarland H; European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board. Kappos L, et al. Among authors: weinshenker b. Neurology. 2004 Nov 23;63(10):1779-87. doi: 10.1212/01.wnl.0000145561.08973.4f. Neurology. 2004. PMID: 15557490
Clinical outcomes assessment in multiple sclerosis.
Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Rudick R, et al. Among authors: weinshenker b. Ann Neurol. 1996 Sep;40(3):469-79. doi: 10.1002/ana.410400321. Ann Neurol. 1996. PMID: 8797541 Review.
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. McDonald WI, et al. Among authors: weinshenker by. Ann Neurol. 2001 Jul;50(1):121-7. doi: 10.1002/ana.1032. Ann Neurol. 2001. PMID: 11456302
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B; EVIDENCE Study Group. EVidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Panitch H, et al. Among authors: weinshenker b. Neurology. 2002 Nov 26;59(10):1496-506. doi: 10.1212/01.wnl.0000034080.43681.da. Neurology. 2002. PMID: 12451188 Clinical Trial.
Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B; EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Panitch H, et al. Among authors: weinshenker b. J Neurol Sci. 2005 Dec 15;239(1):67-74. doi: 10.1016/j.jns.2005.08.003. Epub 2005 Sep 19. J Neurol Sci. 2005. PMID: 16169561 Clinical Trial.
350 results